Skip to main content

Asthma News

News
While interventions using community health workers appear to show promise in improving certain aspects of asthma-related disease burden in adults in the United States, more studies are needed to confirm their effectiveness in adults with respiratory disease, according to a systematic review…
News
An electronic alert prompting emergency providers at a children’s hospital to prescribe asthma controller medication for patients with poorly controlled asthma was effective, according to a study published online in the Journal of Asthma. The study included children ages 4 through 14 presenting to…
News
Recent research published online in the Journal of Asthma shows that monitoring emergency department (ED) visit frequency can help predict future asthma-related hospitalization risk. “Resource limitations and low rates of follow-up with primary care providers currently limit the impact of ED-based…
News
According to a recent study, despite numerous effective treatments for asthma, a significant faction of patients do not achieve sustained asthma control and could be faced with increased financial burden and decreased quality-adjusted life years (QALY).  J Mark FitzGerald, MD, professor in the…
News
Patients initiating mepolizumab for asthma appear to have a greater disease burden compared with patients initiating omalizumab, according to a study recently published in Allergy and Asthma Proceedings. “Real-world data on the characteristics and burden of disease among patients with asthma…
Conference Insider
In an abstract presented at the 2019 AAAAI Annual Meeting, researchers explained that the prevalence of asthma in opioid dependent patients is greater than the national prevalence of asthma.  According to the Centers for Disease Control and Prevention, the national prevalence of asthma is 8.3%.…
Conferences
Implementation of the Asthma Adherence Pathway among treatment physicians helped to improve adherence to Dulera (mometasone furoate, formoterol fumarate dihydrate inhalation; Merck) and improved asthma control, according to data from a late-breaker study presented at the 2017 AAAAI Annual Meeting…
News
By Reuters Staff LONDON (Reuters) - The first new asthma pill in decades has produced promising results in a small clinical trial, potentially paving the way for another treatment option for patients by the end of the decade. Fevipiprant, a prostaglandin D2 receptor 2 antagonist, was tested in 61…
News
LONDON | BY BEN HIRSCHLER (REUTERS) GlaxoSmithKline has bought global rights to an experimental drug from Johnson & Johnson for up to 175 million pounds ($230 million), raising its bet on a new generation of biotech medicines for severe asthma. The British drugmaker recently launched Nucala,…
Back to Top